Puma Biotechnology's Competitors, Revenue, Number of Employees, Funding, Acquisitions & News - Owler Company Profile
Implied Volatility Surging for Puma Biotechnology (PBYI) Stock Options
3 Stocks Tumbling This Month: Clovis Oncology, Hyperion Therapeutics, and Puma Biotechnology - San Antonio Express-News
Puma Biotechnology Presents Results from the Phase II SUMMIT Trial of Neratinib for ERBB2 (HER2) Mutant, HER2 Non-Amplified, Metastatic Breast Cancer at the 2019 San Antonio Breast Cancer Symposium
Puma Biotechnology Announces Publication of Interim Results of Phase II CONTROL Trial in Annals of Oncology | Business Wire
Puma Biotechnology
PUMA decreases the growth of prostate cancer PC-3 cells independent of p53
Puma brings back its RS-Computer smart running shoe from the 1980s
Puma Biotechnology Presents Interim Results of Phase Ib/II FB-10 Trial of PB272 in Combination with Trastuzumab Emtansine (T-DM1) in HER2-Positive Metastatic Breast Cancer at the 2018 ASCO Annual Meeting
Press Releases — Strata Oncology
Puma Biotechnology and Strata Oncology Announce Collaboration to Accelerate Enrollment in Neratinib HER2 Mutation Basket Study (SUMMIT Trial) | Business Wire
Puma Biotechnology enters into a collaborative agreement with Strata Oncology
Is Puma off the cancer M&A list? With Nerlyx marketing deal, some investors think so | FiercePharma
Puma Biotechnology
Puma Biotechnology
Puma Biotechnology
JP Morgan Healthcare, Day 3: Puma Biotechnology, Natera | Precision Oncology News
Puma Bio to adjust proposed labeling for neratinib after meeting with CHMP oncology advisory group; shares up 2% after hours By Seeking Alpha
Puma Biotech: Wounded Predator Ready To Jump Back (NASDAQ:PBYI) | Seeking Alpha
2E) SAO/
Knight Therapeutics licences cancer drug from Puma Biotechnology
Puma Biotechnology
